Answers are grounded in this paper and cite their sources.
Reveals selective inhibition of HDAC8 in malignancies, suggesting new therapeutic pathways.
Histone deacetylase 8 (HDAC8), a zinc-dependent class I enzyme, plays key roles in regulating gene expression and is implicated in various malignancies. Although hydroxamic acid-based inhibitors, like PCI-34051, have demonstrated potent HDAC8 inhibition, limitations including poor selectivity, instability, and off-target effects underscore the need for novel scaffolds. Here, we designed and synthesized a series of indole-based (thio)barbiturate derivatives to identify selective HDAC8 inhibitors. Compound 3d showed promising potency (IC 50 = 2.9 μM) and selectivity for HDAC8 over other isoforms. Structure–activity relationship studies revealed that thiobarbituric acid and 2-methylindole scaffolds enhanced HDAC8 inhibition. Remarkably, compound 3r emerged as the most potent inhibitor (IC 50 = 0.08 μM), exhibiting slow-binding kinetics, nanomolar potency, and high selectivity over HDAC1, 2, 3, and 6. Furthermore, compound 3r selectively induced SMC3 hyperacetylation in THP-1 cells, confirming its functional HDAC8 inhibition. Computational modeling and molecular dynamics simulations rationalized the experimental SAR and suggested an allosteric mechanism of inhibition.
No takes yet. Share an insight, caveat, or question.
Elsayed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: